Prognostic value of matrix metalloproteinase-2 protein and matrix metalloproteinase-9 protein in colorectal cancer: a meta-analysis

被引:4
作者
Wang, Yusha [1 ,2 ]
Wei, Yuhao [1 ]
Huang, Jing [3 ]
Li, Xinke [4 ]
You, Diqing [5 ]
Wang, Li [2 ]
Ma, Xuelei [1 ]
机构
[1] Sichuan Univ, West China Hosp, Canc Ctr, Dept Biotherapy,State Key Lab Biotherapy, Chengdu, Sichuan, Peoples R China
[2] Sichuan Univ, West China Hosp, Lung Canc Ctr, Chengdu, Sichuan, Peoples R China
[3] Sichuan Univ, West China Hosp, Dept Med Ultrasound, 37 Guoxue Lane, Chengdu 610041, Sichuan, Peoples R China
[4] Sichuan Univ, West China Clin Med Coll, Chengdu, Sichuan, Peoples R China
[5] Sichuan Acad Med Sci & Sichuan Prov Peoples Hosp, Sch Med UESTC, Chengdu, Peoples R China
关键词
Matrix metalloproteinase-2 (MMP-2); Matrix metalloproteinase-9 (MMP-9); Colorectal cancer (CRC); Prognosis; Meta-analysis; PREDICTS POOR SURVIVAL; HIGH EXPRESSION; STAGE-II; MMP-2; CHEMOTHERAPY; INHIBITORS; EFFICACY;
D O I
10.1186/s12885-024-12775-9
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction Matrix metalloproteinase-2 (MMP-2) and matrix metalloproteinase-9 (MMP-9) are critical components of the extracellular matrix (ECM) in colorectal cancer (CRC). We aimed to evaluate the prognostic value of MMP-2 and MMP-9 in patients with CRC. Methods We performed a meta-analysis of cohort studies with available data on the effect of MMP-2 and MMP-9 expression on both disease-free survival (DFS) and overall survival (OS) by the risk ratios (RRs) with their 95% confidence intervals (CIs). Studies were subgrouped based on the different tissue types, including cancer tissue and normal tissue, and the subgroup effect of MMP expression in different tissues was analyzed through meta-regression. To ensure the quality and reduce the risk of bias, the Newcastle-Ottawa Scale (NOS) was used to assess the included studies. A sensitivity analysis was randomly performed to assess the potential impact of each study on our results. Results Eighteen trials were selected (Table 1) and included a total of 3944 patients. According to our primary meta-analysis, the expression of MMP-2 was significantly associated with a decrease in OS (RR = 1.75, 95% CI = 1.34 to 2.29, P < 0.001) and DFS (RR = 2.62, 95% CI = 1.25 to 5.49, P < 0.001), and the expression of MMP-9 was not significantly associated with a decrease in OS (RR = 1.48, 95% CI = 0.97 to 2.24, P = 0.069) or DFS (RR = 1.60, 95% CI = 0.87 to 2.94, P = 0.133). According to the subgroup analysis of MMPs in different tissues, high MMP-2 expression in cancer tissue (RR = 1.90, 95% CI = 1.29 to 2.79) and normal tissue (RR = 1.59, 95% CI = 1.17 to 2.17) were significant indicators of poor OS. High MMP-2 expression in cancer tissue was significant indicator of poor DFS (RR = 2.12, 95% CI = 1.09 to 4.11). MMP-9 expression was also associated with poor OS (RR = 1.40, 95% CI = 0.85 to 2.29), but the difference in OS between the high and low expression groups was not statistically significant. Conclusions High MMP-2 expression, especially in cancer tissue, is significantly associated with both poor DFS and poor OS in patients with CRC. High MMP-9 expression tended to indicate a poor prognosis of CRC but the correlation was not significant.
引用
收藏
页数:13
相关论文
共 42 条
[1]   Novel computational and drug design strategies for inhibition of human papillomavirus-associated cervical cancer and DNA polymerase theta receptor by Apigenin derivatives [J].
Akash, Shopnil ;
Bayil, Imren ;
Hossain, Md. Saddam ;
Islam, Md. Rezaul ;
Hosen, Md. Eram ;
Mekonnen, Amare Bitew ;
Nafidi, Hiba-Allah ;
Bin Jardan, Yousef A. ;
Bourhia, Mohammed ;
Bin Emran, Talha .
SCIENTIFIC REPORTS, 2023, 13 (01)
[2]   Prognostic and diagnostic implications of MMP-2, MMP-9, and VEGF-α expressions in colorectal cancer [J].
Araujo, R. F., Jr. ;
Lira, G. A. ;
Vilaca, J. A. ;
Guedes, H. G. ;
Leitao, M. C. A. ;
Lucena, H. F. ;
Ramos, C. C. O. .
PATHOLOGY RESEARCH AND PRACTICE, 2015, 211 (01) :71-77
[3]   Metalloproteinase inhibitors: biological actions and therapeutic opportunities [J].
Baker, AH ;
Edwards, DR ;
Murphy, G .
JOURNAL OF CELL SCIENCE, 2002, 115 (19) :3719-3727
[4]   Multidrug Resistance in Cancer: Understanding Molecular Mechanisms, Immunoprevention and Therapeutic Approaches [J].
Bin Emran, Talha ;
Shahriar, Asif ;
Mahmud, Aar Rafi ;
Rahman, Tanjilur ;
Abir, Mehedy Hasan ;
Siddiquee, Mohd. Faijanur-Rob ;
Ahmed, Hossain ;
Rahman, Nova ;
Nainu, Firzan ;
Wahyudin, Elly ;
Mitra, Saikat ;
Dhama, Kuldeep ;
Habiballah, Mahmoud M. ;
Haque, Shafiul ;
Islam, Ariful ;
Hassan, Mohammad Mahmudul .
FRONTIERS IN ONCOLOGY, 2022, 12
[5]   Prognostic significance of matrix metalloproteinase-9 (MMP-9) in stage II colorectal carcinoma [J].
Buhmeida A. ;
Bendardaf R. ;
Hilska M. ;
Collan Y. ;
Laato M. ;
Syrjänen S. ;
Syrjänen K. ;
Pyrhönen S. .
Journal of Gastrointestinal Cancer, 2009, 40 (3-4) :91-97
[6]   Increased matrix metalloproteinase 2 concentration and transcript expression in advanced colorectal carcinomas [J].
Chan, CC ;
Menges, M ;
Orzechowski, HD ;
Orendain, N ;
Pistorius, G ;
Feifel, G ;
Zeitz, M ;
Stallmach, A .
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2001, 16 (03) :133-140
[7]   Matrix metalloproteinase-9 activity is associated with poor prognosis in T3-T4 node-negative colorectal cancer [J].
Cho, Yong Beom ;
Lee, Woo Yong ;
Song, Sang Yong ;
Shin, Hee Jung ;
Yun, Seong Hyeon ;
Chun, Ho-Kyung .
HUMAN PATHOLOGY, 2007, 38 (11) :1603-1610
[8]   Clinical management of metastatic colorectal cancer in the era of precision medicine [J].
Ciardiello, Fortunato ;
Ciardiello, Davide ;
Martini, Giulia ;
Napolitano, Stefania ;
Tabernero, Josep ;
Cervantes, Andres .
CA-A CANCER JOURNAL FOR CLINICIANS, 2022, 72 (04) :372-401
[9]   Colorectal cancer [J].
Dekker, Evelien ;
Tanis, Pieter J. ;
Vleugels, Jasper L. A. ;
Kasi, Pashtoon M. ;
Wallace, Michael B. .
LANCET, 2019, 394 (10207) :1467-1480
[10]   Synergistic efficacy of Cullin1 and MMP-2 expressions in diagnosis and prognosis of colorectal cancer [J].
Deng, Jianliang ;
Chen, Wenjiao ;
Du, Yuan ;
Wang, Weiming ;
Zhang, Guoqiang ;
Tang, Yuehua ;
Qian, Zhangjun ;
Xu, Ping ;
Cao, Zhihong ;
Zhou, Yan .
CANCER BIOMARKERS, 2017, 19 (01) :57-64